CorVel Corporation
NASDAQ:CRVLInsurance - Brokers
-$0.07 today
- Market cap
- $4.47B
- Beta
- 0.98
- P/E (TTM)
- 26.9
- EPS (TTM)
- $2.16
Volume 0.26M
Average 0.22M
CRVL Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
CorVel CorporationNASDAQ: CRVL
Research & Development · Q2 FY2027 · quarter ended Sep 2026
Research & development remains negative
Q2 FY2027 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2026, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2026
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 0 | — |
| FY2025 | 2025-03-31 | 0 | — |
| FY2024 | 2024-03-31 | 0 | — |
| FY2023 | 2023-03-31 | 0 | — |
| FY2022 | 2022-03-31 | 0 | — |
Research & Development vs competitors
How CRVL compares with its peers on the latest reported figures
- CRVL's LTM Sep 2026 research & development of $0 is the 2nd highest of the 4 companies compared; the peer median is $0.
- Research & development amounts to 0.0% of revenue for CRVL, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $277.96M | +10.7% | +10.7% | 20.4% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
CTEVClaritev Corporation | LTM Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding CRVL) | $0 | +10.7% | +10.7% | 0.0% | |
Competitors are the stored peer set for CRVL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 646.23M | 718.56M | 795.31M | 895.59M | 958.53M |
| Cost of Revenue | 494.12M | 560.3M | 623.62M | 685.86M | 725.66M |
| Gross Profit | 152.11M | 158.26M | 171.69M | 209.73M | 232.86M |
| Gross Margin | 23.5% | 22.0% | 21.6% | 23.4% | 24.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 67.6M | 73.71M | 76.59M | 88.9M | 89.73B |
| Operating Expenses | 67.6M | 73.71M | 76.59M | 88.9M | 89.73M |
| Depreciation & Amortization | 23.92M | 25.12M | 26.25M | 29.54M | 31.76M |
| EBITDA | 108.43M | 109.68M | 121.35M | 150.36M | 174.9M |
| EBITDA Margin | 16.8% | 15.3% | 15.3% | 16.8% | 18.2% |
| Operating Income | 84.51M | 84.55M | 95.1M | 120.82M | 143.13M |
| Operating Margin | 13.1% | 11.8% | 12.0% | 13.5% | 14.9% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 0 | 0 | 0 | 0 | 0 |
| Income Before Tax | 84.51M | 84.55M | 95.1M | 120.82M | 143.13M |
| Pre-Tax Margin | 13.1% | 11.8% | 12.0% | 13.5% | 14.9% |
| Income Tax Expense | 18.1M | 18.19M | 18.85M | 25.66M | 32.79M |
| Net Income | 66.41M | 66.37M | 76.25M | 95.17M | 110.34M |
| Net Margin | 10.3% | 9.2% | 9.6% | 10.6% | 11.5% |
| EPS (Basic) | 1.25 | 1.28 | 1.48 | 1.85 | 2.15 |
| EPS (Diluted) | 1.22 | 1.26 | 1.47 | 1.83 | 2.14 |
| Weighted Avg Shares | 53.26M | 51.98M | 51.37M | 51.39M | 51.28M |
| Weighted Avg Shares (Diluted) | 54.38M | 52.78M | 52.04M | 52.04M | 51.63M |
CorVel Corporation
NASDAQ:CRVL
Intrinsic Alpha fair value
Locked
Current Price
$88.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.